Haemonetics Corporation (NYSE:HAE) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.42 per share for the quarter.
Haemonetics Corporation (NYSE:HAE) last announced its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The company had revenue of $211.00 million during the quarter, compared to analysts’ expectations of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. Haemonetics Corporation’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.25 earnings per share. On average, analysts expect Haemonetics Corporation to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of Haemonetics Corporation (HAE) opened at $47.12 on Monday. Haemonetics Corporation has a 52-week low of $33.09 and a 52-week high of $47.98. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.57 and a quick ratio of 1.72. The stock has a market cap of $2,478.81, a PE ratio of 29.27, a PEG ratio of 3.73 and a beta of 0.91.
Several research firms recently weighed in on HAE. Zacks Investment Research cut shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Morgan Stanley reaffirmed an “equal weight” rating and set a $43.00 price objective (up previously from $38.00) on shares of Haemonetics Corporation in a research report on Friday, October 6th. JMP Securities raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Thursday, July 13th. Finally, Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $45.83.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/06/haemonetics-corporation-hae-to-release-quarterly-earnings-on-tuesday.html.
About Haemonetics Corporation
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
What are top analysts saying about Haemonetics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Haemonetics Corporation and related companies.